Annovis Bio, Inc.
Company Name | Annovis Bio, Inc. |
Stock Symbol | ANVS |
On April 29, 2024, Annovis announced that its Alzheimer’s drug, buntanetap, had shown significant results in a subgroup of patients. However, the subgroup was a fraction of the total planned patients, indicating that the drug failed to show statistical significance in meeting its endpoints.
On this news, Annovis’s stock price fell $10.37, or 59.6%, to close at $7.28 per share on April 29, 2024, thereby injuring investors.
Submit Your Information
If you suffered a loss on your Annovis Bio, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.